News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The company is making its entry into the Hyderabad market through its unique asset-light business model
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Subscribe To Our Newsletter & Stay Updated
